Abstracts/Lung Cancer II (1994) 323-344

predicts overall savings from tilgrastim use in a clinical setting in which the risk of febrile ncutropenia is high for patients not receiving tilgrastim. The Medicare and cost models predict only a partial recapture of the cost of tilgrastim thempy. The health care resources Impact of tilgmstim was sensitive to the risk of hospitalisation with febrile neutropenia, and to the perspective chosen for measuring resourceutilisation(charges,wstsorMedicarepaymmts). Theadjunctive use of tilgrastim following myelosuppressive chemotherapy leads to partial orcompleterecaptureofthecostofpurchasingandadministering the product.

Carboplatin and etoposideas outpatient treatment of advanced non-small cell lung cancer Pronzato P, Lrnducci M, Vaira F, Vigatti A, Be&Ii G. Unira Operariva di OncO&ia Medica, Ospedale S Andrea, I-19100 La Spazia. Chemothenpy (Switzerland) 1994;40: 144-8.

Twenty-four outpatients with IocnJly advanced (inoperable or unsuitable for radical radiotherapy) or metastatic non-small-cell lung cancer were tre&ed with carboplatin (300 mglm day I) + etoposide (120 mgP day I-3). every 3 weeks. Two patients died of di- progression before completing at last 2 cycles of c-y. Four patimts(16.796)obtainedrpartialmsponse. 10haddiaeasestabilizntion (41.7%) and 8 progressed (33.3%). Medirut ovetaB survival was 8 months (range l-22). Toxicity was moderate, with no nephro-. neuro- or ototoxicity.

Combination chemotherapy with carboplatin and etoposide against lung adenocarcinoma in a patient undergoing hemodialysis: A case report Yanagawa H. Takiahita Y. Bando H. Shinohara T. Tanaka H. Sumitani H. Depr. of Respiratory Medicine. Tokushima Prrfrctural Central Hosp., Tokushima. Jpa J Cancer Chemother 1993;20:2409-1 I.

A 60-yearold male with chronic renal failure undergoing hemodialysis was treated with combination chemotherapy with carboplatin and etoposide against stage IV adenccatcinoma of the lung. Three hundred mg/mr of carboplatin 011 day 1, and 50 mg/mr of etoposide on days I and 3 were injected intravenously before hemodialysis. Pharmacokinetic results revealed that carboplatin was dialyzed. No severe side effects were observed. These. observations suggest that combination chemotherapy with carboplatin and etoposide, .seed to be applicable to the patients with chronic renal failure undergoing hemodialysis.

The selection of antibodies for targeted therapy of small-cell lung cancer (SCLC) using a human tumour spheroid model to compare the uptake of cluster 1 and cluster w4 antibodies Olabiran Y, LedermannJA, Marston NJ, Boxer GM, Hicks R, Souhami RL et a). Deparimenr of Oncology, Univ College London Medical School. 91 RidingHo~eSt.London WIPBBT. BrJCancer1994;69:247- 3‘.

SpheroidsofasmalI-cell lungcancer(SCLC)cell line PDCwere used toevahtate theuptakeand penetrationoftwoantibodiea recognising different SCLC antigens. Spheroids approximately 300400 m in diameter were incubated with I g ml-’ lz’I-labelled NY.3Dl I, an antibody which reacts with the cluster 1 group antigen (neural cell adhesion molecule; NCAM) and [‘aI JSWAI 1, which binds to the cluster w4 antigen. The rate of uptake of both antibodies was similar: an initially rapid phase was seen during the first 8 h and maximum uptake occurred by 24 h. The mean uptake per spheroid at 24 h was 0.97 ng for f’zIfNY.3DI I and0.45ng for[‘zl]SWAll. Anobjectivemeasurement

ofantibcdypmetrationintosphe&dswasdevelopedusingacomputerised imagePnnlysisofimmunastpinedsactionsofspheroids. Tbeconcentration ofantibodyand incubation timaswerevaried. Bothantibcdiespenetrated the spheroids to a depth of 50 m after 30 min. This increased to about lOOmafier4hincubationwith1orl00gmJ’SWAII.Tberesultswith I g ml’ NY.3DII were similar, but in the presence of 100 g ml’ NY.3DI 1 penetration into the spheroid was deep and diffuse. These results demonstrate a major concentration-dependent differenw in the uptake and penetration of cluster 1 and cluster w4 antibodies in this spheroid model and they have implications for the selection ofantibodies for targeted thenpy of SCLC.

Treatment of smallcell lung cancer xenografts with iodine 131-anti-neural cell adhesion molecular monockmal antibody and evaluation of absorbed dose in tissue Hosono M, Endo K. Hosono MN, Kobayashi H. Shirato M, Sakahara H et al. Dept. of Nuclear Medicine, Kyoro University Hospiral, S&o- ku, Kyoto 606-01. J Nucl Med 1994;35:2%-302.

Human small-cell lung cancer (SCLC) is considered a feasible target for immunotherapy using a radiolabeled monoclonal antibody (Mab). A murine Mab, NE150 (&$I), reacts with the neural cell adhesion molecule, which is identical to cluster 1 antigen of SCLC. Mefhti: To estimate their therapeutic effects, NE150 and an isotype- matchedcontrolMobwerelPbeledwith”’IMddministersdintnvenously as a single dose into athymic mice inoculated with a NCI-H69 SCLC xenograft. The absorbed dose in organs was also examined based upon a long-term biodistrihution study of “‘I- NEISO. Results: Tumors (initial volun~ 563.4 k 223.5 mm’) treated with 1 I. 1 MBq (300 Ci) of “‘I-NElSOdiminishedPndhrameinvisibleat~ys3~33,&~~rat~g a 60&y mean growth delay to reach a tripled initial volume compared with sham-treated tumors. Cumulative absorbed doses were estimated to be 23 10, 410. 500. 330. and 790 cGy for the tumor, liver, kidney, spleen and lung, respectively. Conclusion: Iodine-l31-NE150 had potent therapeutic effects against SCLC transplants in athymic mice, however, careful assessment of the side effects, improvement of radioiodination and chimerization of the Mah might be necessary to achieve efficient targeting in clinical therapeutic applications.

Vinorelbine versus vinorelbine plus cisplatin in advanced non- small cell lung cancer: A randomized trial Depicm A. Chaszg C. Quoix E. Lebeau B, Blanchon F. Paillot N et al. Service de Pneumologie. CHR. F-25&M Besancon. Ann Oncol 19’?4:5:37-42.

Purpose: The purpose of the study was to assess the possible benefit of the combination vinorelbine (NVB)-cisplatin (DDP) in comparison with NVB alone in advanced non-small cell lung cancer (NSCLC), not treated previously. It also involved confirmation of the efficacy of vinorelbine as monotherapy. Pcllienfs and merhods: In this pb III trial, 231 eligible patients were stratified by centre and randomized to receive either NVB alone, 30 mg/m’/week or the combination of NVB 30 mg/m]/week and DDP 80 mglmrl3 weeks. Patients were to be treated for a minimum of6 weeks, with first response assessment performed 9 weeks after the beginning of treatment. Resulfs: The two groups differed in terms of objective response rates (I6 R and 43%. respectively, p = O.ooOl) and median time to progression (10 weeks and 20 weeks, p = 0.0001). However, the difference was not significant for median survival time (32 weeks, 33 weeks, p = 0.48). The addition of DDP resulted in an increase in toxicity, in particular tenal. hematologic. neurologicandemetic. This toxicity led to treatment discotttimutimt in 8% and 21% ofpatients. respectively. Respectively 3% and 13% of patients stopped treatment early during objective